FDA Accepts Supplement for Vorasidenib (Voranigo) by Servier
The FDA has accepted a supplemental application for Vorasidenib (Voranigo) from Servier.
Asset / Drug
Drug and asset intelligence for Servier with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.